Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2478
Real-time Quote. Real-time Tradegate - 10/24 02:54:47 pm
84.958 EUR   +0.07%
49m ago Exclusive - Unipharm hires Houlihan Lokey to explore $500 million sale -..
59m agoDJFlu-Shot Supply Dented by Production Woes
1h agoDJFlu-Shot Supply Dented by Production Woes
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

04/24/2012 | 03:39pm US/Eastern

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
Latest news on SANOFI
49m ago Exclusive - Unipharm hires Houlihan Lokey to explore $500 million sale -sourc..
59m agoDJFlu-Shot Supply Dented by Production Woes
1h agoDJFlu-Shot Supply Dented by Production Woes
1h ago GENZYME : BioMarin Announces Third Quarter 2014 Financial Results
9h agoDJSanofi SA 3Q 2014-- Forecast
9h ago SANOFI : Information concerning the total number of voting rights and shares
1d ago GENZYME : iTraumaCare Positions New Leader for Next-Level Growth
1d agoSANOFI SA : quaterly earnings release
1d ago SANOFI : Restates Commitment to Wellness in Nigeria
1d ago GENZYME : Reports Results from Two Phase III Studies
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF